Takeda's Zasocitinib Shows Superior Skin Clearance In Phase 3 Psoriasis Trial

TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Ltd. (TAK,4502.T) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis.Zasocitinib is an investigational oral tyrosine kinase 2 (TYK2) inhibitor.According to the c…